Author

B. Nehete

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. Grattoni· 1 shared C. Y. X. Chua· 1 shared D. Nerguizian· 1 shared D. Zhou· 1 shared F. Abdelmawla· 1 shared F. P. Pons-Faudoa· 1 shared H. He· 1 shared H. Lu· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Grattoni

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ultra-long-acting refillable nanofluidic implant confers full protection against SHIV infection in non-human primates

F. P. Pons-Faudoa, N. Di Trani, S. Capuani, J. N. Campa-Carranza, B. Nehete, S. Sharma, K. A. Shelton, L. R. Bushman, F. Abdelmawla, M. Williams, L. Roon, D. Nerguizian, C. Y. X. Chua, M. M. Ittmann, J. E. Nichols, , A. Grattoni

An ultra-long-acting refillable nanofluidic implant sustained islatravir levels in non-human primates for 20 months and provided 100% protection against SHIV infection.

bioRxiv · Dec 15, 2022 · PreprintBioengineering

Function of ex vivo stimulated Natural killer T cells from patients with chronic HIV-1 infection

P. Thapa, P. Nehete, H. He, B. Nehete, S. Buchl, L. Bull, H. Lu, R. Arduino, K. J. Sastry, D. Zhou

This study shows that NKT cells from HIV-1 infected patients can be expanded and produce antiviral cytokines when stimulated with ex vivo dendritic cells loaded with alpha-galactosylceramide, except in advanced AIDS patients.

bioRxiv · Nov 5, 2019 · PreprintImmunology